 Big Rock Partners Acquisition Corp NASDAQ: BRPA shares are trading higher after the companys SPAC merger target, NeuroRx, on Monday confirmed dosing of the first patient in a Phase 3 trial of ZYESAMI was announced by the NIH last week. The trial, designated as ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19, will study ZYESAMI to treat severely ill COVID-19 patients. 